Offering with U.S. Healthcare consists of loan carrying 16.5% coupon
By Devika Patel
Knoxville, Tenn., Nov. 17 - K-V Pharmaceutical Co. completed a $60 million term loan with U.S. Healthcare I, LLC and U.S. Healthcare II, LLC on Nov. 17, according to an 8-K filed Wednesday with the Securities and Exchange Commission.
The financing includes an immediate funding of $60 million under a credit agreement. The lenders have also committed to lend up to $120 million in additional funding through a term loan conditional upon certain milestones, $60 million of which will be used to repay the initial $60 million loan under the credit agreement and $20 million that may be drawn upon FDA approval of Gestiva.
The initial $60 million loan pays a 16.5% coupon, 11.5% of which must be paid in cash with 5% payable in kind. It is due in March 2013.
The investors also received warrants for 12,587,511 shares, which are exercisable at $1.62. The strike price reflects a 23.22% premium to the Nov. 16 closing share price of $2.11.
The company is obligated to use about $20 million of the loan proceeds to repay debt, interest and closing fees owed to the lenders.
K-V is a St. Louis specialty pharmaceutical company.
| Issuer: | K-V Pharmaceutical Co.
|
| Issue: | Term loan
|
| Amount: | $60 million
|
| Maturity: | March 2013
|
| Coupon: | 16.5%
|
| Price: | Par
|
| Yield: | 16.5%
|
| Warrants: | For 12,587,511 shares
|
| Warrant strike price: | $1.62
|
| Investors: | U.S. Healthcare I, LLC and U.S. Healthcare II, LLC
|
| Settlement date: | Nov. 17
|
| Stock symbol: | NYSE: KV.A
|
| Stock price: | $2.42 at close Nov. 17
|
| Market capitalization: | $120.64 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
